Voyager Therapeutics (VYGR) Ratios
Voyager Therapeutics Ratios
MX:VYGR's free cash flow for Q2 2026 was $-25.84M. For the 2026 fiscal year, MX:VYGR's free cash flow was increased by $0.00 and operating cash flow was $-25.84M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.64 | 5.56 | 4.96 | 1.72 | 2.68 |
| Quick Ratio | 7.64 | 5.56 | 4.96 | 1.72 | 2.68 |
| Cash Ratio | 2.46 | 1.43 | 1.07 | 1.36 | 2.30 |
| Solvency Ratio | -2.06 | -0.65 | 1.19 | -0.40 | -0.67 |
| Operating Cash Flow Ratio | -4.99 | -0.31 | 1.21 | -0.17 | -1.05 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 146.49M | $ 183.52M | $ 204.72M | $ 24.16M | $ 37.90M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.14 | 0.11 | 0.06 | 0.15 | 0.23 |
| Debt-to-Equity Ratio | 0.19 | 0.15 | 0.09 | 0.39 | 0.46 |
| Debt-to-Capital Ratio | 0.16 | 0.13 | 0.08 | 0.28 | 0.32 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.29 | 1.31 | 1.49 | 2.70 | 2.04 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.62 | 0.76 | 0.47 | 0.60 | 1.17 |
| Net Debt to EBITDA | 0.25 | 0.46 | -0.38 | 1.91 | 1.07 |
| Profitability Margins | |||||
| Gross Profit Margin | -227.62% | 100.00% | 63.13% | -36.32% | -97.21% |
| EBIT Margin | -296.17% | -80.42% | 48.80% | -112.05% | -196.76% |
| EBITDA Margin | -286.12% | -74.51% | 50.58% | -96.92% | -182.96% |
| Operating Profit Margin | -326.56% | -104.11% | 48.80% | -124.27% | -196.76% |
| Pretax Profit Margin | -296.17% | -80.42% | 53.49% | -113.41% | -190.29% |
| Net Profit Margin | -296.53% | -81.25% | 52.93% | -113.45% | -190.29% |
| Continuous Operations Profit Margin | -296.53% | -81.25% | 52.93% | -113.45% | -190.29% |
| Net Income Per EBT | 100.12% | 101.03% | 98.95% | 100.03% | 100.00% |
| EBT Per EBIT | 90.70% | 77.25% | 109.61% | 91.26% | 96.71% |
| Return on Assets (ROA) | -47.46% | -16.54% | 37.67% | -29.12% | -36.73% |
| Return on Equity (ROE) | -61.06% | -21.68% | 56.00% | -78.63% | -74.90% |
| Return on Capital Employed (ROCE) | -58.41% | -24.26% | 42.55% | -58.59% | -51.53% |
| Return on Invested Capital (ROIC) | -56.44% | -23.76% | 41.63% | -56.74% | -49.59% |
| Return on Tangible Assets | -47.46% | -16.54% | 37.67% | -29.12% | -36.73% |
| Earnings Yield | -51.90% | -19.88% | 36.44% | -19.83% | -69.74% |
| Efficiency Ratios | |||||
| Receivables Turnover | 22.93 | 17.81 | 2.96 | 64.02 | 50.02 |
| Payables Turnover | 26.39 | 0.00 | 57.46 | 21.73 | 128.55 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.97 | 1.68 | 8.33 | 1.23 | 0.68 |
| Asset Turnover | 0.16 | 0.20 | 0.71 | 0.26 | 0.19 |
| Working Capital Turnover Ratio | 0.20 | 0.33 | 1.63 | 0.59 | 0.29 |
| Cash Conversion Cycle | 2.09 | 20.49 | 116.95 | -11.09 | 4.46 |
| Days of Sales Outstanding | 15.92 | 20.49 | 123.30 | 5.70 | 7.30 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 13.83 | 0.00 | 6.35 | 16.80 | 2.84 |
| Operating Cycle | 15.92 | 20.49 | 123.30 | 5.70 | 7.30 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.26 | -0.27 | 1.81 | -0.33 | -1.42 |
| Free Cash Flow Per Share | -2.30 | -0.33 | 1.74 | -0.39 | -1.46 |
| Dividend Paid and CapEx Coverage Ratio | -51.03 | -4.35 | 23.93 | -5.02 | -33.27 |
| Capital Expenditure Coverage Ratio | -51.03 | -4.35 | 23.93 | -5.02 | -33.27 |
| Operating Cash Flow Coverage Ratio | -3.63 | -0.35 | 3.84 | -0.54 | -1.21 |
| Operating Cash Flow to Sales Ratio | -3.28 | -0.19 | 0.31 | -0.31 | -1.43 |
| Free Cash Flow Yield | -58.56% | -5.76% | 20.56% | -6.41% | -54.01% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.93 | -5.02 | 2.74 | -5.04 | -1.43 |
| Price-to-Sales (P/S) Ratio | 5.71 | 4.09 | 1.45 | 5.72 | 2.73 |
| Price-to-Book (P/B) Ratio | 1.18 | 1.09 | 1.54 | 3.96 | 1.07 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.71 | -17.36 | 4.86 | -15.60 | -1.85 |
| Price-to-Operating Cash Flow Ratio | -1.74 | -21.36 | 4.66 | -18.70 | -1.91 |
| Price-to-Earnings Growth (PEG) Ratio | -0.02 | 0.04 | -0.01 | 0.16 | 0.01 |
| Enterprise Value Multiple | -1.75 | -5.02 | 2.49 | -3.99 | -0.42 |
| Enterprise Value | 201.86M | 299.33M | 314.59M | 158.14M | 28.83M |
| EV to EBITDA | -1.75 | -5.02 | 2.49 | -3.99 | -0.42 |
| EV to Sales | 5.00 | 3.74 | 1.26 | 3.87 | 0.77 |
| EV to Free Cash Flow | -1.49 | -15.90 | 4.21 | -10.54 | -0.52 |
| EV to Operating Cash Flow | -1.52 | -19.55 | 4.04 | -12.64 | -0.54 |
| Tangible Book Value Per Share | 3.34 | 5.20 | 5.49 | 1.54 | 2.52 |
| Shareholders’ Equity Per Share | 3.34 | 5.20 | 5.49 | 1.54 | 2.52 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.01 | 0.01 | -0.00 | 0.00 |
| Revenue Per Share | 0.69 | 1.39 | 5.81 | 1.07 | 0.99 |
| Net Income Per Share | -2.04 | -1.13 | 3.08 | -1.21 | -1.89 |
| Tax Burden | 1.00 | 1.01 | 0.99 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.10 | 1.01 | 0.97 |
| Research & Development to Revenue | 3.34 | 1.59 | 0.37 | 1.49 | 1.97 |
| SG&A to Revenue | 0.90 | 0.45 | 0.14 | 0.76 | 1.00 |
| Stock-Based Compensation to Revenue | 0.37 | 0.18 | 0.04 | 0.23 | 0.30 |
| Income Quality | 1.11 | 0.24 | 0.59 | 0.27 | 0.75 |
Currency in USD
